Previous 10 | Next 10 |
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces that the company is scheduled to participate in the H.C. Wainwright 21 st Annual Global Investment Conference in New York City. Presentation takes place on Tuesday, September 10, 2019 at 8:45 a.m. Eastern Time. John Higgins, CEO,...
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) partner CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and accelerating the launch of innovative therapeutics and pharmaceutical products in China, the U.S., and throughout the world, annou...
Insider buying increased significantly last week with insiders purchasing $128.07 million of stock last week compared to $75.89 million in the week prior. Selling also increased significantly with insiders selling $3.09 billion of stock last week compared to $584.61 million in the week prior. ...
Call Start: 09:00 Call End: 09:49 Ligand Pharmaceuticals Incorporated (LGND) Q2 2019 Earnings Conference Call July 30, 2019, 9:00 am ET Company Participants Todd Pettingill - Senior Director, Corporate Development & IR John Higgins - CEO Matt Foehr - COO Matt Korenberg ...
Thinly traded Ligand Pharmaceuticals ( LGND -10.7% ) slumps on more than double normal volume, albeit on turnover of only 867K shares, following its Q2 earnings release and conference call earlier today. More news on: Ligand Pharmaceuticals Incorporated, Healthcare stocks news, Stocks on...
Ligand Pharmaceuticals ( LGND ) Q2 results : Revenues: $25M (-72.2%); Royalties: $6.6M (-79.0%); Material sales: $8.5M (+11.8%); License fees, milestones and other revenues: $9.8M (-80.8%). More news on: Ligand Pharmaceuticals Incorporated, Healthcare stocks news, Earnings news and commen...
Ligand Pharmaceuticals (NASDAQ: LGND ): Q2 Non-GAAP EPS of $0.68 beats by $0.02 ; GAAP EPS of -$0.74 misses by $1.40 . More news on: Ligand Pharmaceuticals Incorporated, Earnings news and commentary, Healthcare stocks news, Read more ...
Conference Call Begins at 9:00 a.m. Eastern Time Today Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today reported financial results for the three and six months ended June 30, 2019, and provided an operating forecast and program updates. Ligand management will host a conferenc...
AER , AGCO , AME , AOS , ARCC , BEN , BERY , CEQP , CIGI , CMCO , CMI , CNX , CNXM , COP , CVLT , DHI , DORM , DSX , ECL , EME , EQM , ETN , EXLS , FDP , FMS , GEO , GLT , GLW , GPN , GRUB , GTX , HCA , HUBB , HUD , HUN , I , INCY , IPGP , IR , IRWD ,...
Strengthens and expands its OmniAb platform offering Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces the signing of an agreement with Ab Initio Biotherapeutics whereby Ligand will acquire Ab Initio for $12 million in cash. Ab Initio was a privately held antigen-discove...
News, Short Squeeze, Breakout and More Instantly...
Ligand Pharmaceuticals Incorporated Company Name:
LGND Stock Symbol:
NASDAQ Market:
Ligand Pharmaceuticals Incorporated Website:
2024-08-02 00:22:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-30 06:30:09 ET RBC Capital analyst issues OUTPERFORM recommendation for LGND on July 30, 2024 03:16AM ET. LGND was trading at $108.75 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 6 - Buy recomm...
2024-07-30 06:00:04 ET Douglas Miehm from RBC Capital issued a price target of $130.00 for LGND on 2024-07-30 03:16:00. The adjusted price target was set to $130.00. At the time of the announcement, LGND was trading at $108.75. The overall price target consensus is at $1...